COURTNEY FLYNN: Open Payments
NPI 1306166905 · EAGLE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$645 in 33 payments from 14 companies in 2025. Trend: 2023 $623 · 2024 $1,037 · 2025 $645
Food & beverage: $620Education: $25
| Company | Payments | Amount |
|---|---|---|
| Grifols USA, LLC | 5 | $107 |
| AstraZeneca Pharmaceuticals LP | 6 | $105 |
| Regeneron Healthcare Solutions, Inc. | 4 | $84 |
| Novartis Pharmaceuticals Corporation | 4 | $80 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Ionis Pharmaceuticals, Inc. | 2 | $39 |
| Amgen Inc. | 2 | $37 |
| Genentech USA, Inc. | 1 | $31 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $20 |
Products named: Prolastin-C Liquid, DUPIXENT, TEZSPIRE, Xolair, TRELEGY ELLIPTA, AIRSUPRA, Rhapsido, NEFFY.
Industry payments across ID — which companies pay providers there.
